TY - JOUR
AR - RGM-2022-2-101
TI - Pharmacological Potential of Advance Diabetes Support Product in the Management of Insulin-Dependent Diabetes: Overviews on Case Study
AU - Shridhar, Pandya
AU - Chetan, Savaliya
AU - Kamlesh, Thummar
AU - Dheeraj, Nagore
JO - International Journal of Regenerative Medicine
PY - 2022
DA - Fri 16, Sep 2022
SN - 2613-5914
DO - http://dx.doi.org/10.31487/j.RGM.2022.02.01
UR - https://www.sciencerepository.org/pharmacological-potential-of-advance_RGM-2022-2-101 
KW - Type I diabetes, type II diabetes, nutraceutical, pancreatic beta cells
AB - Type I or Type II diabetes, once recognized as juvenile diabetes or insulin-dependent diabetes, is a chronic illness in which the pancreas produces slight or no insulin. Insulin-dependent diabetes is a syndrome of glucose homeostasis considered by autoimmune destruction of the insulin-producing pancreatic Beta-cell that gradually leads to insulin deficiency. As there is no perfect treatment for management, Gplife has thought of and developed a product that is found to be effective in the management of insulin-dependent diabetes. After 60 days of evaluation of cases, it is observed that fasting blood glucose was reduced by 62.25%, postprandial glucose levels were reduced by 62.37%, HBA1C levels were reduced by 39.57%, C Peptide levels were increased by 26.67%, also the external insulin injection requirement of the patient’s decreased by 88.57%. This case study gives an overview of the current understanding of the disease and the efficacy of advance diabetic support products in insulin-dependent diabetes. It is evident that the said product further helps to reduce insulin and OHA doses for the management of insulin-dependent diabetes. It is suggested that the advance diabetes support product should be further extensively used as a monotherapy or adjunctive therapy for the regulation, or management or control of insulin-dependent diabetes.